Case Report: Successful Treatment of Steroid-Refractory Immune Checkpoint Inhibitor-Related Pure Red Cell Aplasia With Cyclosporin-Reference-Cited by-同舟云学术

Case Report: Successful Treatment of Steroid-Refractory Immune Checkpoint Inhibitor-Related Pure Red Cell Aplasia With Cyclosporin

Published:2020-08-28 Issue: Volume:10 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Gérard Alexandre,Romani Serena,Van-Obberghen Elise,Fresse Audrey,Muzzone Marine,Parassol Nadège,Boscagli Annick,Rocher Fanny,Borchiellini Delphine,Drici Milou-Daniel

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference19 articles.

1. Opdivo (Nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma.;Raedler;Am Health Drug Benefits.,2015

2. Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis.;Almutairi;Front Oncol.,2020

3. Autoimmune hemolytic anemia as a complication of nivolumab therapy.;Palla;Case Rep Oncol.,2016

4. case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma.;Yuki;Melanom Res.,2017

5. Bone Marrow findings of immune-mediated pure red cell aplasia following anti-programmed cell death receptor-1 therapy: a report of two cases and review of literature.;Le Aye;J Hematol.,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First Reported Case of Pure Red Cell Aplasia Related to Sotorasib;Internal Medicine;2024

2. Waldenström macroglobulinemia with secondary pure red cell aplasia in a patient with metastatic castrate resistant prostate cancer receiving an immune checkpoint inhibitor: a case report;Journal of Medical Case Reports;2023-05-28

3. The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity;Translational Oncology;2023-02

4. Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large‐scale pharmacovigilance analysis;International Immunopharmacology;2023-01

5. Nivolumab;Reactions Weekly;2020-10